Barinthus Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	129.97	142.09	194.39	214.05	43.27	11.43
Cash & Cash Equivalents	129.97	142.09	194.39	214.05	43.27	11.43
Cash Growth	-8.53%	-26.90%	-9.19%	394.74%	278.46%	-
Receivables	0	0	5.85	0.02	0.52	0.99
Other Current Assets	13.16	14.82	12.81	12.69	4.12	3.83
Total Current Assets	143.13	156.91	213.04	226.77	47.9	16.25
Property, Plant & Equipment	18.94	19.4	15.71	9.09	2.77	2.79
Goodwill and Intangibles	36.53	37.32	40.48	44.06	0	0
Other Long-Term Assets	0.89	0.88	0.98	0.8	0	0
Total Long-Term Assets	56.35	57.6	57.16	53.95	2.77	2.79
Total Assets	199.48	214.51	270.21	280.72	50.67	19.04
Accounts Payable	1.16	1.6	3.75	2.42	4.67	3.89
Deferred Revenue	1.43	0	0	0.18	0.25	0.27
Current Debt	1.91	1.79	0.43	0.68	0.19	0.17
Other Current Liabilities	8.33	9.21	8.06	7.88	2.54	1.42
Total Current Liabilities	12.84	12.6	12.24	11.16	7.64	5.75
Long-Term Debt	10.9	11.19	8.34	6.54	46.17	1.61
Other Long-Term Liabilities	3.73	3.72	6.42	10.46	0	0
Total Long-Term Liabilities	14.63	14.91	14.76	17	46.17	1.61
Total Liabilities	27.47	27.51	27	28.15	53.81	7.36
Total Debt	12.81	12.98	8.77	7.22	46.36	1.78
Debt Growth	-1.31%	47.91%	21.48%	-84.42%	2507.98%	-
Retained Earnings	-192.08	-176.59	-103.24	-108.59	-57.72	-37.89
Comprehensive Income	-24.9	-23.32	-33.46	-8.49	-1.24	-0.47
Shareholders' Equity	171.83	186.78	242.9	252.13	-36.91	-22.45
Net Cash / Debt	117.17	129.11	185.61	206.83	-3.1	9.65
Net Cash / Debt Growth	-9.25%	-30.44%	-10.26%	-	-	-
Net Cash Per Share	3.02	3.36	4.86	7.99	-0.39	0.41
Working Capital	130.3	144.31	200.8	215.61	40.26	10.5
Book Value Per Share	4.43	4.87	6.52	9.74	-4.67	-0.96

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).